What Biopharma Leaders Need from Strategy Consultants
Growth-stage biopharma companies have access to more market and scientific information than ever, but the real challenge is connecting the signals before committing capital. A development plan may look promising on its own, even as investor appetite, competing programs, patent activity or regulatory changes suggest otherwise. The value of a consulting partner lies not in the volume of analysis it delivers, but in how effectively it turns primary-source intelligence into decisions about development priorities and capital allocation.
Reliable intelligence starts with the quality of the sources behind it. Search tools and general-purpose AI can make research faster, but they cannot replace the work of checking where evidence comes from and understanding how one development affects another. Buyers should look for providers that use primary records and bring together information from company filings, regulatory sources, clinical activity and intellectual property. The real value lies in connecting these pieces to see the bigger picture, not in collecting more documents.
Experience at the decision table matters just as much. Growth-stage companies often have scientific leadership that knows the asset deeply but has less experience with financing, scaling, company building and board-level tradeoffs. Advice becomes more useful when the people shaping strategy have lived through those decisions and can challenge the original framing of a problem. A provider should be able to test whether the requested path is actually the best path, rather than simply producing analysis around the brief it was given. Senior involvement also affects how quickly a recommendation can be translated into action when circumstances change.
“Katogen also provides experienced fractional support for vendor selection and project management, with additional help around financing and communications when needed.”
How a consulting engagement is structured can reveal whether senior expertise is hands-on or simply part of the pitch. Buyers should ask who will actually do the work, how closely they can work with experienced operators and whether those experts stay involved when recommendations meet real-world constraints such as vendors, timelines, budgets and board expectations. Ultimately, direct access to experienced people who take responsibility for the work can matter more than the size of the consulting team.
Execution matters just as much as strategy. Early-stage biopharma companies often keep their teams small and rely on outside partners to fill the gaps. But a good plan can lose momentum if a consulting firm steps away before implementation begins. Buyers should look for partners who can help put plans into action, manage projects and bring in experienced fractional talent when needed. That support may also extend to financing and communications as the company advances. The goal is not to build a management team out of consultants, but to give a lean team the expertise it needs, when it needs it.
Katogen combines AI-supported intelligence with senior operators who can move from analysis into execution for growth-stage biopharma companies. Its platform draws from 101 primary sources and hundreds of millions of primary documents, giving strategy work a broad evidence base rather than a narrow market snapshot. Katogen also provides experienced fractional support for vendor selection and project management, with additional help around financing and communications when needed. Its senior team can also provide CEO mentoring and board support when founders need experienced guidance around company-building decisions. That model gives founders access to business experience without requiring a full internal team. For buyers that need both intelligence and hands-on execution, Katogen merits consideration as a biopharma strategy consulting partner.
